These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 21156818

  • 1. Role for NAD(P)H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(allylamino)-17-demethoxygeldanamycin-induced heat shock protein 90 inhibition in pancreatic cancer cells.
    Siegel D, Shieh B, Yan C, Kepa JK, Ross D.
    J Pharmacol Exp Ther; 2011 Mar; 336(3):874-80. PubMed ID: 21156818
    [Abstract] [Full Text] [Related]

  • 2. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition.
    Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, Ross D.
    Cancer Res; 2005 Nov 01; 65(21):10006-15. PubMed ID: 16267026
    [Abstract] [Full Text] [Related]

  • 3. The bioreduction of a series of benzoquinone ansamycins by NAD(P)H:quinone oxidoreductase 1 to more potent heat shock protein 90 inhibitors, the hydroquinone ansamycins.
    Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, Ross D.
    Mol Pharmacol; 2006 Oct 01; 70(4):1194-203. PubMed ID: 16825487
    [Abstract] [Full Text] [Related]

  • 4. Stability of the Hsp90 inhibitor 17AAG hydroquinone and prevention of metal-catalyzed oxidation.
    Guo W, Siegel D, Ross D.
    J Pharm Sci; 2008 Dec 01; 97(12):5147-57. PubMed ID: 18393300
    [Abstract] [Full Text] [Related]

  • 5. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90.
    Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P.
    J Natl Cancer Inst; 1999 Nov 17; 91(22):1940-9. PubMed ID: 10564678
    [Abstract] [Full Text] [Related]

  • 6. The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activity in vivo.
    Douglas M, Lim AR, Porter JR, West K, Pink MM, Ge J, Wylie AA, Tibbits TT, Biggs K, Curtis M, Palombella VJ, Adams J, Fritz CC, Normant E.
    Mol Cancer Ther; 2009 Dec 17; 8(12):3369-78. PubMed ID: 19952119
    [Abstract] [Full Text] [Related]

  • 7. Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells.
    Gaspar N, Sharp SY, Pacey S, Jones C, Walton M, Vassal G, Eccles S, Pearson A, Workman P.
    Cancer Res; 2009 Mar 01; 69(5):1966-75. PubMed ID: 19244114
    [Abstract] [Full Text] [Related]

  • 8. 5-Methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, exhibits activity against human pancreatic cancer in vitro and in vivo.
    Dehn DL, Siegel D, Zafar KS, Reigan P, Swann E, Moody CJ, Ross D.
    Mol Cancer Ther; 2006 Jul 01; 5(7):1702-9. PubMed ID: 16891456
    [Abstract] [Full Text] [Related]

  • 9. Use of NQO1 status as a selective biomarker for oesophageal squamous cell carcinomas with greater sensitivity to 17-AAG.
    Hadley KE, Hendricks DT.
    BMC Cancer; 2014 May 15; 14():334. PubMed ID: 24886060
    [Abstract] [Full Text] [Related]

  • 10. Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
    Maloney A, Clarke PA, Naaby-Hansen S, Stein R, Koopman JO, Akpan A, Yang A, Zvelebil M, Cramer R, Stimson L, Aherne W, Banerji U, Judson I, Sharp S, Powers M, deBilly E, Salmons J, Walton M, Burlingame A, Waterfield M, Workman P.
    Cancer Res; 2007 Apr 01; 67(7):3239-53. PubMed ID: 17409432
    [Abstract] [Full Text] [Related]

  • 11. p53 independent radio-sensitization of human lymphoblastoid cell lines by Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
    Fujii Y, Kato T, Kubota N, Fujimori A, Niwa O, Okayasu R.
    Oncol Rep; 2010 Jan 01; 23(1):199-203. PubMed ID: 19956882
    [Abstract] [Full Text] [Related]

  • 12. Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: relevance for toxicity and mechanism of action.
    Guo W, Reigan P, Siegel D, Ross D.
    Drug Metab Dispos; 2008 Oct 01; 36(10):2050-7. PubMed ID: 18635747
    [Abstract] [Full Text] [Related]

  • 13. Development of indolequinone mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1): NQO1 inhibition and growth inhibitory activity in human pancreatic MIA PaCa-2 cancer cells.
    Reigan P, Colucci MA, Siegel D, Chilloux A, Moody CJ, Ross D.
    Biochemistry; 2007 May 22; 46(20):5941-50. PubMed ID: 17455910
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A mechanistic and structural analysis of the inhibition of the 90-kDa heat shock protein by the benzoquinone and hydroquinone ansamycins.
    Reigan P, Siegel D, Guo W, Ross D.
    Mol Pharmacol; 2011 May 22; 79(5):823-32. PubMed ID: 21285336
    [Abstract] [Full Text] [Related]

  • 17. HSP27 expression levels are associated with the sensitivity of hepatocellular carcinoma cells to 17-allylamino-17-demethoxygeldanamycin.
    Cui Y, Wu W, Zhou Y, Xie Q, Liu T, Jin J, Liu K.
    Future Oncol; 2013 Mar 22; 9(3):411-8. PubMed ID: 23469976
    [Abstract] [Full Text] [Related]

  • 18. 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.
    Tse AN, Sheikh TN, Alan H, Chou TC, Schwartz GK.
    Mol Pharmacol; 2009 Jan 22; 75(1):124-33. PubMed ID: 18820127
    [Abstract] [Full Text] [Related]

  • 19. Heat shock protein 90 inhibitor attenuates renal fibrosis through degradation of transforming growth factor-β type II receptor.
    Noh H, Kim HJ, Yu MR, Kim WY, Kim J, Ryu JH, Kwon SH, Jeon JS, Han DC, Ziyadeh F.
    Lab Invest; 2012 Nov 22; 92(11):1583-96. PubMed ID: 22964853
    [Abstract] [Full Text] [Related]

  • 20. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models.
    Chung YL, Troy H, Banerji U, Jackson LE, Walton MI, Stubbs M, Griffiths JR, Judson IR, Leach MO, Workman P, Ronen SM.
    J Natl Cancer Inst; 2003 Nov 05; 95(21):1624-33. PubMed ID: 14600095
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.